Summit Therapeutics Share Discussion Threads

[football] 17/11/2016 13:48

with so many buy ratings you would think the share price would be higher than it is



11/16/2016 – Summit Therapeutics plc had its “outperform” rating reiterated by analysts at RBC Capital

[abergele] 16/11/2016 19:40

Hugos Maximus, and Waterloo,
nice replies,I will tackle our local Welsh MP as you say.
also all that research and report here,,many thanks for the info.

[freemoney1] 16/11/2016 16:11

Sorry...last post...been reading around, but this backs up my maths :

"The Company anticipates reporting data periodically during this trial with 24-week muscle biopsy data from the first group of patients enrolled expected to be reported in January 2017."

[freemoney1] 16/11/2016 16:03

We may have to wait a little longer for F6 results, but hopefully we'll get indication of efficacy of F3 sooner.

Reminder from 24th August :

• Incorporation of ezutromid formulation F6 into the ongoing PhaseOut DMD Phase 2 proof-of-concept trial (subject to regulatory approval). The plan is to evaluate F6 in up to 10 of the 40 patients the trial expects to enroll, and to compare the F6 and F3 formulation variants back-to-back in longer-term dosing. Initial data are expected to be released in mid-2017.

[freemoney1] 16/11/2016 15:50

Yes, enrolment RNS for UK was 17th June. With one month screening period and 24 weeks dosing to first biopsy they should start collecting results mid January onwards. Also since it's open label I guess we could get talk of other results like 6mwt any time from here onwards. I think I remember they would be looking at the boys at 12 week intervals.
Obviously we do not know how many boys they have so far and if the number is significant to build any meaningful data earlier than Q2/3 2017.
Either way, the first half of next should be exciting...fingers crossed for all involved.

Where is the C.Diff deal... come on, pick a partner and get that drug to market!

[waterloo01] 16/11/2016 15:26

Hopefully (toward the end 2nd Q possible). Thought US would tick up today, knowing how much they like local news!

Also worth noting what's not said. They have been dosing in the UK and to open in the US there can't have been to date any adverse events.

[hugus maximus] 16/11/2016 14:21

Some info about DMD action would be really great in the 2nd Quarter. There no longer seems to be any reason why not?

[hugus maximus] 16/11/2016 14:18

abergele ... we are all baffled by this too.
It would great to think that C Diff (which has a cure in RZD) is no longer the killer it once was as a result of Summit's drug. Folk seem to be more frightened about the possibility of picking up C Diff in hospital than any problems related directly to procedures.

[waterloo01] 16/11/2016 13:03

Upgraded from $26 - $29 from Royal bank Canada.

[waterloo01] 16/11/2016 12:21

looking good for 1st readout 2nd Q.

[freemoney1] 16/11/2016 12:20

We're up and running in the US.
Great news for all the DMD families and wishing them all the best through this potential life changing trial. GLA

[waterloo01] 16/11/2016 08:00

Cheers football. abergele, Sorry to hear that, especially when we think we know we have a cure. I'd write to your MP and ask them why it isn't approved yet.

[abergele] 15/11/2016 22:11

Please excuse my selfish view,
but as a pensioner,and this countries full of them, and a recent death by an uncle with cdif...this is the biggest mover of SUMM rather than the dmd..IMO..
or do the governments want the old folk to die,to depleate the surplus population
....sounds familiar of the"Scroogue" scenarios we will get this winter again on the box.

[waterloo01] 15/11/2016 18:35

Anyone else having ADVFN issues with a huge half screen pop up from some kitchen company? How do you block it?

[hugus maximus] 15/11/2016 14:15

I know the final results will be a wee while but isn't some data for RDZ v FDX trials due for release?

[waterloo01] 15/11/2016 11:10

Glyn has said repeatedly that he want's to make the FDA's job easy for them to approve.

RDZ new however is getting rather overdue. What the nature and shape of the deal is anyone's guess at the moment. Still hoping for some upfront but have to accept might not be any?

[chrisatrdg] 15/11/2016 10:59

Hi All - I appreciate waterloo01's postings and agree with Hugus Maximus that it would appear that Summit have been very careful in ensuring that their methods of research are tight & more likely to get approval from the FDA.Tortoise & Hare comes to mind Summit being the Tortoise.

[hugus maximus] 15/11/2016 09:08

Morning Waterloo .. it must be said Summit have done a great job in making the process watertight re: biomarkers and number of patents in trial etc. The FDA can certainly not take issue with their results in the way they did with Sarpeta .. if they can prove it works under the conditions they've set out ... open and shut case! (Edit - i.e. IMO following the protocol of any bill )

[waterloo01] 15/11/2016 07:46

Rather resonates with our approach re biomarkers.

One thing the bill proposes is increased funding for the National Institutes of Health (NIH) and clinical research. But it also proposes changes to how drugs are approved, increasing the use of surrogate markers. Forbes notes, “Monitoring biochemical markers as a stand-in for disease progression has been useful for hepatitis and HIV treatment, but has been disastrous in other areas, like statins, diabetes, oncology and hormone replacement therapy.”

[sorrento06] 15/11/2016 06:54

I've really had my fill of this company. What annoys me most is the awful communication with investors.

[joe shone] 14/11/2016 21:11

good finish on nasdaq.perhaps a xmas present, fingers crossed gl,joe.

[chrisatrdg] 14/11/2016 08:46

I hope you are wrong Sorrento06 but it seems to me all of Summits energies are for driving DMD but we still might be in for a C-Diff surprise before Xmas would make for a good present.

[sorrento06] 14/11/2016 07:41

I think at 35 I might die of old age before this C-Diff deal gets announced.